As previously reported, Wells Fargo analyst Derek Archila downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26. The firm is moving to the sidelines following Biogen’s (BIIB) announced acquisition of the company. Wells expects the deal to close in Q2 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis downgraded to Equal Weight from Overweight at Wells Fargo
- Tesla upgraded, AppLovin initiated: Wall Street’s top analyst calls
- Apellis price target raised to $41 from $21 at RBC Capital
- 3 Best Trending Stocks, According to Analysts – 4/2/2026
- Apellis price target raised to $41 from $20 at Mizuho